Skip to main content
EBS
NYSE Life Sciences

Director Louis W. Sullivan Files Intent to Sell Shares After Option Exercise, Following Recent Sales

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
7
Price
$13.985
Mkt Cap
$730.028M
52W Low
$4.02
52W High
$14.06
Market data snapshot near publication time

Summary

Director Louis W. Sullivan filed a Form 144 to sell 25,748 shares, valued at $360,142, after exercising options, adding to over $1.3 million in sales in the last three months.


Key Events

  • Director Files Intent to Sell

    Director Louis W. Sullivan filed a Form 144 to sell 25,748 shares of common stock, valued at approximately $360,142, following a stock option exercise.

  • Recent Insider Selling Activity

    This proposed sale follows previous sales by Mr. Sullivan of 104,695 shares, generating approximately $1.34 million in gross proceeds over the past three months.

  • Stock Trading Near 52-Week High

    The intent to sell comes as Emergent BioSolutions' stock is trading near its 52-week high, potentially indicating a move to lock in gains.


Analysis

Director Louis W. Sullivan has filed a Form 144 indicating an intent to sell 25,748 shares of Emergent BioSolutions common stock, valued at approximately $360,142. This proposed sale follows the exercise of stock options. Notably, Mr. Sullivan has already sold 104,695 shares for gross proceeds of approximately $1.34 million in the past three months. The cumulative selling activity by a director, especially with the stock trading near its 52-week high, suggests a pattern of monetizing equity holdings. While the proposed sale itself is modest, the overall trend of insider selling could be interpreted as a lack of conviction in the company's near-term upside by a board member.

At the time of this filing, EBS was trading at $13.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $730M. The 52-week trading range was $4.02 to $14.06. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EBS - Latest Insights

EBS
May 28, 2026, 4:04 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $9.35
Real-time Price: $8.32 info
Change: -$1.03 (-11%) info
Market Cap: $429.281M info
EBS
May 18, 2026, 8:59 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.25
Real-time Price: $8.32 info
Change: +$0.070 (+0.85%) info
Market Cap: $429.281M info
EBS
Apr 30, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.98
Real-time Price: $8.32 info
Change: -$0.660 (-7%) info
Market Cap: $429.281M info
EBS
Apr 30, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.11
Real-time Price: $8.32 info
Change: -$0.790 (-9%) info
Market Cap: $429.281M info
EBS
Apr 30, 2026, 7:55 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.00
Real-time Price: $8.32 info
Change: +$0.320 (+4%) info
Market Cap: $429.281M info
EBS
Apr 30, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.00
Real-time Price: $8.32 info
Change: +$0.320 (+4%) info
Market Cap: $429.281M info
EBS
Apr 29, 2026, 7:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.27
Real-time Price: $8.32 info
Change: +$0.050 (+0.60%) info
Market Cap: $429.281M info
EBS
Apr 28, 2026, 8:01 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.10
Real-time Price: $8.32 info
Change: +$0.220 (+3%) info
Market Cap: $429.281M info
EBS
Apr 22, 2026, 4:50 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $8.29
Real-time Price: $8.32 info
Change: +$0.030 (+0.36%) info
Market Cap: $429.281M info
EBS
Apr 16, 2026, 5:51 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.70
Real-time Price: $8.32 info
Change: -$0.3752 (-4%) info
Market Cap: $429.281M info